A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
EudraCT / EU CT No
2022-501560-17-00
Protocol No
MK1026-010
Trial information
Medical condition
R/R CLL/SLL
Trial phase
Phase 3
Sponsor
MSD
Start date
02/07/2026
Main objective
PFS
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Alexandroupolis
University General Hospital of Alexandroupolis
Hematology Clinic
Ioannis Kotsianidis
2551353154
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.
